SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial fo...
Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase III trial after a 19-m...
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumpt...
Stock analysts at StockNews.com began coverage on shares of SCYNEXIS (NASDAQ:SCYX – Get Free Report)...